AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$TWST

Leproust Emily M. sold $56.3M of TWST

Leproust Emily M. (Chief Executive Officer) sold 356,546 shares of Twist Bioscience Corp (TWST) at an average of $157.99 ($151.46–$163.39, $56.33M total) across 13 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Sep 21, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
high confidence
Mentioned
$TWST
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishMed
01

Why it matters

The reduction in insider ownership may be interpreted as reduced confidence, influencing short‑term price action.

02

Market read

Primary insider sell of significant size; traders may consider adjusting positions in TWST.

03

What to watch

Potential tax planning or diversification motives for the CEO; no immediate operational concerns.

Relevance 7/10Novelty 7/10Timing: post‑market 2026‑09‑21

Background

Form 4 filings disclose insider transactions; a $56M sell by the CEO is noteworthy for investors.

Company-level read

Ticker impact

$TWSTBearishHigh confidence
Context

CEO Emily Leproust sold 356,546 shares for $56.3M via a 10b5‑1 plan, reducing her stake to 620,589 shares.

Expected impact

Potential short‑term dip as market digests the sizable sell‑off.

Evidence & confidence

The transaction size ($56M) is material for a mid‑cap biotech and is disclosed via a primary Form 4 filing.

Market effects

Sector

May prompt scrutiny of other biotech insider activity and could affect sector sentiment.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global impact beyond TWST shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • person
    Emily M. Leproust

    Chief Executive Officer of Twist Bioscience Corp.

  • company
    Twist Bioscience Corp.

    Biotech company listed on NASDAQ under ticker TWST.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 8
$TWSTMed

Jefferies initiates Twist Bioscience stock at Hold on valuation

Jefferies initiated coverage on Twist Bioscience (TWST) with a Hold rating and $150 price target, citing premium valuation. The stock trades at $155.65 after a 391% YTD surge. Jefferies notes its market differentiation and AI-driven growth, but warns of high valuation expectations. TWST partners with Eli Lilly's TuneLab for AI/ML drug discovery, while BWS Financial rates it Sell, and Guggenheim reiterates Buy.

investing.com2 min
OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min